ScoreWhy is Keros Therapeutics, Inc. ?
1
The company has declared positive results for the last 2 consecutive quarters
- NET SALES(HY) At USD 32.43 MM has Grown at 7,530.59%
- OPERATING CASH FLOW(Y) Highest at USD 88.79 MM
- ROCE(HY) Highest at 10.43%
2
With ROE of 9.16%, it has a very attractive valuation with a 0.64 Price to Book Value
- Over the past year, while the stock has generated a return of -3.44%, its profits have risen by 135.5% ; the PEG ratio of the company is 0.1
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Keros Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Keros Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Keros Therapeutics, Inc.
0.18%
-1.59
48.74%
S&P 500
16.12%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
150.53%
EBIT Growth (5y)
26.25%
EBIT to Interest (avg)
-81.74
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.11
Tax Ratio
71.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0.14%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
7
Industry P/E
Price to Book Value
0.64
EV to EBIT
-5.52
EV to EBITDA
-5.34
EV to Capital Employed
-19.37
EV to Sales
-0.98
PEG Ratio
0.05
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
9.16%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend26What is working for the Company
NET SALES(HY)
At USD 32.43 MM has Grown at 7,530.59%
OPERATING CASH FLOW(Y)
Highest at USD 88.79 MM
ROCE(HY)
Highest at 10.43%
DEBTORS TURNOVER RATIO(HY)
Highest at 65.9 times
RAW MATERIAL COST(Y)
Fallen by -432.54% (YoY
CASH AND EQV(HY)
Highest at USD 1,383.69 MM
PRE-TAX PROFIT(Q)
At USD -8.7 MM has Grown at 83.56%
NET PROFIT(Q)
At USD -7.28 MM has Grown at 86.25%
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Keros Therapeutics, Inc.
Net Sales
At USD 32.43 MM has Grown at 7,530.59%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Debtors Turnover Ratio
Highest at 65.9 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Operating Cash Flow
Highest at USD 88.79 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD -8.7 MM has Grown at 83.56%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -7.28 MM has Grown at 86.25%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Cash and Eqv
Highest at USD 1,383.69 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by -432.54% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
